Pulmonary hypertension associated with chronic lung disease (PH-CLD) meets precapillary PH criteria. Less is known CLD patients with “early vasculopathy,” a phenotype characterized by elevated pulmonary vascular resistance (PVR) and normal mean pulmonary artery pressure (mPAP).
Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit Sotatercept improves small airway disease and hyperinflation in patients with pulmonary hypertension
Catheter-directed thrombolysis (CDL) and mechanical thrombectomy (MT) are increasingly used for intermediate–high–risk pulmonary embolism (PE), yet comparative long-term outcomes remain uncertain. We aimed to compare the effectiveness and safety of CDL versus MT in real-world clinical practice.
Pregnancy poses substantial risks for women with Pulmonary Arterial Hypertension (PAH). This study aimed to evaluate maternal and neonatal outcomes in a contemporary PAH cohort under modern management, specifically investigating whether vasoreactive status warrants distinct clinical recommendations.
Sotatercept has recently expanded treatment options for pulmonary arterial hypertension (PAH), but its mental health and quality-of-life impact is not well characterized. We assessed psychiatric diagnoses and patient-reported outcomes in PAH patients treated with sotatercept within the clinical trial program.
Pulmonary arterial hypertension (PAH) involves complex vascular remodeling. The hypoxia-inducible factor (HIF) pathway is a central oxygen-sensing mechanism, but its circulating profile in PAH is poorly defined. This case-control study included 71 patients with PAH and 93 age- and sex-matched healthy controls.
Pulmonary arterial hypertension (PAH) is associated with significant symptoms and impaired health-related quality of life (HRQOL) and survival. Specialty palliative care (SPC), an intervention delivered by a multidisciplinary team, is focused on improving HRQOL.
